- Home
- TSI vs GOSS Comparison
TSI vs GOSS Comparison
Compare TSI & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TSI | GOSS |
|---|---|---|
| Founded | 1987 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 234.6M | 796.2M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | TSI | GOSS |
|---|---|---|
| Price | $4.97 | $3.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.60 |
| AVG Volume (30 Days) | 106.8K | ★ 4.4M |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 7.46% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $44,051,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $6.41 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.48 | $0.76 |
| 52 Week High | $4.87 | $3.87 |
Technical Indicators
Market Signals| Indicator | TSI | GOSS |
|---|---|---|
| Relative Strength Index (RSI) | 61.51 | 44.42 |
| Support Level | $4.90 | $3.14 |
| Resistance Level | $4.96 | $3.87 |
| Average True Range (ATR) | 0.03 | 0.30 |
| MACD | 0.00 | -0.08 |
| Stochastic Oscillator | 100.00 | 1.85 |
Price Performance
Historical ComparisonAbout TSI TCW Strategic Income Fund Inc.
Tcw Strategic Income Fund Inc operates as a closed-end management investment company. Its investment objective is to seek a total return comprised of current income and capital appreciation by investing in a wide range of securities. The company invests in a range of industries, such as airlines, banks, beverages, biotechnology, chemicals, computers, diversified financial services, entertainment and others.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.